What is the Return on Assets (ROA) of Amgen this year?
The Return on Assets (ROA) of Amgen is 0.07 undefined this year.
Amgen ROA 2024
Amgen ROA
0.07
Ticker
AMGN
ISIN
US0311621009
WKN
867900
In 2024, Amgen's return on assets (ROA) was 0.07, a -31.28% increase from the 0.1 ROA in the previous year.
Amgen Aktienanalyse
What does Amgen do?
Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Amgen revenue by segment
In the annual report of the Amgen share (US0311621009, 867900, AMGN), it breaks down its revenues into 2 segments: 1. Human Therapeutics, 2. Other. The Amgen stock (WKN: 867900, ISIN: US0311621009, Ticker Symbol: AMGN) is a leading investment for investors interested in participating in the Health Care sector.
95 % Human Therapeutics
5 % Other
ROA Details
Understanding Amgen's Return on Assets (ROA)
Amgen's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Amgen's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Amgen's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Amgen’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Amgen stock
What was the ROA of Amgen compared to the previous year?
The ROA of Amgen has increased by -31.28% compared to the previous year.
What consequences do high ROA have for investors of Amgen?
A high ROA is advantageous for investors of Amgen, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Amgen?
A low ROA can be unfavorable for investors of Amgen as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Amgen affect the company?
An increase in ROA of Amgen can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Amgen impact the company?
A reduction in the ROA of Amgen can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Amgen?
Some factors that can influence the ROA of Amgen include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Amgen important for investors?
The ROA of Amgen is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Amgen take to improve ROA?
To improve ROA, Amgen can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Amgen pay?
Over the past 12 months, Amgen paid a dividend of 8.52 USD . This corresponds to a dividend yield of about 2.67 %. For the coming 12 months, Amgen is expected to pay a dividend of 14.1 USD.
What is the dividend yield of Amgen?
The current dividend yield of Amgen is 2.67 %.
When does Amgen pay dividends?
Amgen pays a quarterly dividend. This is distributed in the months of March, June, September, December.
How secure is the dividend of Amgen?
Amgen paid dividends every year for the past 19 years.
What is the dividend of Amgen?
For the upcoming 12 months, dividends amounting to 14.1 USD are expected. This corresponds to a dividend yield of 4.42 %.
In which sector is Amgen located?
Amgen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Amgen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Amgen from 12/9/2024 amounting to 2.25 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.
When did Amgen pay the last dividend?
The last dividend was paid out on 12/9/2024.
What was the dividend of Amgen in the year 2023?
In the year 2023, Amgen distributed 7.76 USD as dividends.
In which currency does Amgen pay out the dividend?
The dividends of Amgen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Amgen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Andere Kennzahlen von Amgen
Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
